Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID) - A phase II study

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 1, 2000, Pages 63-68

  Taylor, Penelope R A ^a   Jackson, Graham H ^a   Galloway, Michael J ^b   Soukop, Michael ^c   Tinegate, Hazel ^d   Angus, Brian ^a   Proctor, Stephen J ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b BISHOP AUCKLAND GENERAL HOSPITAL   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Idarubicin; Low grade NHL; Oral chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CHLORAMBUCIL; DEXAMETHASONE; IDARUBICIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033916999     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000124     Document Type: Article

References (21)

1. 1. Aviles A, Diaz-Maqueo JC, Rodriguez L, Garcia EL, Torras V, Guzman R (1990) Group risk classification of non-Hodgkin's lymphoma. Arch Invest Med 21: 11
2. 2. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Celigny P (1997) Comparison in low-tumour-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15: 1110
3. 3. Case DC, Hayes DM, Gerber M, Gams R, Ervin TJ, Dorsk BM (1990) Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. Cancer Res 50: 6833
4. 4. Devesa SS, Fears T (1992) Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 52: 5432S
5. 5. Errante D, Sorio R, Zagonel V, Carbone A, Monfardini S, Tirelli U (1991) A phase II study of oral idarubicin (4-de-methoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma. Am J Clin Oncol 14: 243
6. 6. Fasola G, Fanin R, Gherlinzoni F, Galieni P, Taruscio D, Frezza G, Mazza P, Pileri S, Baccarani M (1984) Serum LDH concentration in non-Hodgkin's lymphomas. Relationship to histologie type, tumor mass, and presentation features. Acta Haematol 72: 231
7. 7. Gall EA, Mallory TB (1942) Malignant lymphomas: clinicopathologic survey of 618 cases. Am J Pathol 18: 381
8. 8. Gillies HC, Herriott D, Liang R, Ohashi K, Rogers HJ, Harper PG (1987) Pharmacokinetics of idarubicin (4-demethoxydaunorubicin IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 23: 303
9. 9. Hermans J, Krol AD, Groningen K van, Kluin PM, Kluin-Nelemans JC, Kramer MH, Noordijk EM, Ong F, Wijermans PW (1995) International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86: 1460
10. 10. Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New Engl J Med 311: 1471
11. 11. Iaffaioli RV, Frasci G, Palmieri G, Tagliaferri P, Montesarchio V, Pagliarulo C, Tortoriello A, Facchini G, Matano E, Lauria R, et al (1995) Chlorambucil, vincristine and cytarabine (COA) treatment of low grade lymphomas. Leuk Lymphoma 17: 147
12. 12. Jones L, Cotter FE, Lord D, Newland AC (1990) Phase 2 study of mitoxantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkin's lymphoma. Hematol Oncol 8: 41
13. 13. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457
14. 14. Lennard AL, Carey PJ, Jackson GH, Proctor SJ (1990) An effective oral combination in advanced relapsed Hodgkin's disease: prednisolone, etoposide, chlorambucil and CCNU. Cancer Chemother Pharmacol 26: 301
15. 15. Leonard RCF, Hayward RL, Prescott RJ, Wang J-X, Allan NC, Barrett A, Das SN, Dawson AA, Heppleston A, Lessells AM, Lucie NP, Lucraft HH, Mackie MJ, MacLaren KS, Parker AC, Proctor SJ, Sarkar TK, Sheehan T, Soukop M, Steward WP, White JM (1991) The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. Ann Oncol 2: 655
16. 16. Lister TA, Cullen MH, Beard ME, Brearley RL, Whitehouse JM, Wrigley PF, Stansfield AG, Sutcliffe SB, Malpas JS, Crowther D (1978) Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. BMJ 1: 533
17. 17. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F (1996) Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14: 1262
18. 18. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 35: 1
19. 19. Solal-Celigny P, Brice P, Brousse N, Gaspard H, Bastion Y, Haioun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau J-L, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Leporrier M (1996) Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude de Lymphomes de l'Adulte. J Clin Oncol 14: 514
20. 20. Tamassia V, Pacciarini MA, Moro E, Piazza E, Vago G, Libretti A (1987) Pharmacokinetic study of intravenous and oral idarubicin in cancer patients. Int J Clin Pharmacol Res 7: 409
21. 21. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva